Literature DB >> 12421353

Identity of adenylyl cyclase isoform determines the G protein mediating chronic opioid-induced adenylyl cyclase supersensitivity.

Hermann Ammer1, Thomas E Christ.   

Abstract

To determine the intracellular signal transduction pathway responsible for the development of tolerance/dependence, the ability of Gzalpha to substitute for pertussis toxin (PTX)-sensitive G proteins in mediating adenylyl cyclase (AC) supersensitivity was examined in the presence of defined AC isoforms. In transiently micro-opioid receptor (OR) transfected COS-7 cells (endogenous inhibitory G proteins: Gialpha2, Gialpha3 and Gzalpha), neither acute (1 micro mol/L) nor chronic morphine treatment (1 micromol/L; 18 h) influenced intracellular cAMP production. Coexpression of the micro -OR together with AC type V and VI fully restored the ability of morphine to acutely inhibit cAMP generation. Chronic morphine treatment further resulted in the development of tolerance/dependence, as assessed by desensitization of the acute inhibitory opioid effect (tolerance) as well as the induction of AC supersensitivity after drug withdrawal (dependence). Specific direction of micro -OR signalling via Gzalpha by both PTX treatment and Gzalpha over-expression had no effect on chronic morphine regulation of AC type V, but completely abolished the development of tolerance/dependence with AC type VI. Similar results were obtained in stably micro -OR-expressing HEK293 cells transiently cotransfected with Gzalpha and either AC type V or VI. Coprecipitation studies further verified that Gzalpha specifically binds to AC type V but not type VI. Taken together, these results demonstrate that in principle each of the OR-activated G proteins per se is able to mediate AC supersensitivity. However, they also indicate that it is the molecular nature of AC isoform that selects and determines the OR-activated G protein mediating tolerance/dependence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421353     DOI: 10.1046/j.1471-4159.2002.01188.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Inhibition and superactivation of the calcium-stimulated isoforms of adenylyl cyclase: role of Gbetagamma dimers.

Authors:  Debora Steiner; Tomer Avidor-Reiss; Ester Schallmach; Daniella Saya; Zvi Vogel
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Prolonged Morphine Treatment Alters Expression and Plasma Membrane Distribution of β-Adrenergic Receptors and Some Other Components of Their Signaling System in Rat Cerebral Cortex.

Authors:  Lucie Hejnova; Jitka Skrabalova; Jiri Novotny
Journal:  J Mol Neurosci       Date:  2017-10-28       Impact factor: 3.444

3.  Genome-Wide Small Interfering RNA Screening Reveals a Role for Cullin3-Really Interesting New Gene Ligase Signaling in Heterologous Sensitization of Adenylyl Cyclase.

Authors:  Zhong Ding; Karin F K Ejendal; Monica Soto-Velasquez; Michael P Hayes; Nicholas Santoro; Martha J Larsen; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2019-12-19       Impact factor: 4.030

4.  The role of N53Q mutation on the rat mu-opioid receptor function.

Authors:  A Rostami; M Rabbani; M Mir-Mohammad-Sadeghi
Journal:  J Biomol Tech       Date:  2010-07

5.  Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells.

Authors:  Andrea L Small-Howard; Lori M N Shimoda; Chaker N Adra; Helen Turner
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

Review 6.  Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Authors:  Tarsis F Brust; Jason M Conley; Val J Watts
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

Review 7.  Expression of Opioid Receptors in Cells of the Immune System.

Authors:  Jana Brejchova; Vladimir Holan; Petr Svoboda
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

8.  Morphine as a Potential Oxidative Stress-Causing Agent.

Authors:  Jitka Skrabalova; Zdenka Drastichova; Jiri Novotny
Journal:  Mini Rev Org Chem       Date:  2013-11       Impact factor: 2.495

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.